{"id":"https://openalex.org/W2008953745","doi":"https://doi.org/10.1016/j.clinthera.2010.10.007","title":"Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers","display_name":"Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers","publication_year":2010,"publication_date":"2010-10-01","ids":{"openalex":"https://openalex.org/W2008953745","doi":"https://doi.org/10.1016/j.clinthera.2010.10.007","mag":"2008953745","pmid":"https://pubmed.ncbi.nlm.nih.gov/21095483"},"language":"en","primary_location":{"id":"doi:10.1016/j.clinthera.2010.10.007","doi":"https://doi.org/10.1016/j.clinthera.2010.10.007","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.clinthera.2010.10.007","pdf_url":null,"source":{"id":"https://openalex.org/S185879095","display_name":"Clinical Therapeutics","issn_l":"0149-2918","issn":["0149-2918","1879-114X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5002503854","display_name":"John D. Davis","orcid":"https://orcid.org/0000-0001-6282-1670","observed_orcids":["https://orcid.org/0000-0001-6282-1670"]},"institutions":[{"id":"https://openalex.org/I189718659","display_name":"Pfizer (United Kingdom)","ror":"https://ror.org/04x4v8p40","country_code":"GB","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I189718659"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"John Davis","raw_affiliation_strings":["Research Clinical Pharmacology, Pfizer Inc, Sandwich, Kent, United Kingdom. john.davis@pfizer.com","Pfizer, Inc., Sandwich, UNITED KINGDOM"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Clinical Pharmacology, Pfizer Inc, Sandwich, Kent, United Kingdom. john.davis@pfizer.com","institution_ids":["https://openalex.org/I189718659"]},{"raw_affiliation_string":"Pfizer, Inc., Sandwich, UNITED KINGDOM","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069631195","display_name":"Frances Hackman","orcid":"https://orcid.org/0009-0009-3178-6329","observed_orcids":["https://orcid.org/0009-0009-3178-6329"]},"institutions":[{"id":"https://openalex.org/I189718659","display_name":"Pfizer (United Kingdom)","ror":"https://ror.org/04x4v8p40","country_code":"GB","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I189718659"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Frances Hackman","raw_affiliation_strings":["Pfizer, Inc., Sandwich, UNITED KINGDOM"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer, Inc., Sandwich, UNITED KINGDOM","institution_ids":["https://openalex.org/I189718659"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084220816","display_name":"Marie-Noella Ndongo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114767","display_name":"Pfizer (Belgium)","ror":"https://ror.org/01zk1vt68","country_code":"BE","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4210114767"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Marie-Noella Ndongo","raw_affiliation_strings":["Pfizer Clinical Research Unit, Erasme, Brussels, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Clinical Research Unit, Erasme, Brussels, Belgium","institution_ids":["https://openalex.org/I4210114767"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039929913","display_name":"Heng Wee Choo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2251586001","display_name":"Singapore General Hospital","ror":"https://ror.org/036j6sg82","country_code":"SG","type":"healthcare","lineage":["https://openalex.org/I2251586001"]}],"countries":["SG"],"is_corresponding":false,"raw_author_name":"HengWee Choo","raw_affiliation_strings":["Pfizer Clinical Research Unit, Singapore General Hospital, Singapore"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Clinical Research Unit, Singapore General Hospital, Singapore","institution_ids":["https://openalex.org/I2251586001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034660908","display_name":"Drew E. Lewis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Drew Lewis","raw_affiliation_strings":["Pfizer Inc, New York, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, New York, New York","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074358267","display_name":"Margaret Tawadrous","orcid":"https://orcid.org/0000-0002-6815-2647","observed_orcids":["https://orcid.org/0000-0002-6815-2647"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Margaret Tawadrous","raw_affiliation_strings":["Pfizer Inc, New London, Connecticut"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, New London, Connecticut","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030678138","display_name":"James Goodrich","orcid":"https://orcid.org/0009-0007-7305-7664","observed_orcids":["https://orcid.org/0009-0007-7305-7664"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"James Goodrich","raw_affiliation_strings":["ViiV Healthcare, Research Triangle Park, North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ViiV Healthcare, Research Triangle Park, North Carolina","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110898331","display_name":"Grant Langdon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189718659","display_name":"Pfizer (United Kingdom)","ror":"https://ror.org/04x4v8p40","country_code":"GB","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I189718659"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Grant Langdon","raw_affiliation_strings":["Pfizer, Inc., Sandwich, UNITED KINGDOM"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer, Inc., Sandwich, UNITED KINGDOM","institution_ids":["https://openalex.org/I189718659"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5002503854"],"corresponding_institution_ids":["https://openalex.org/I189718659"],"apc_list":{"value":4240,"currency":"USD","value_usd":4240},"apc_paid":null,"fwci":1.061,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":{"value":0.76441059,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"32","issue":"11","first_page":"1889","last_page":"1895"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10082","display_name":"HIV/AIDS Research and Interventions","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11655","display_name":"HIV-related health complications and treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/non-nucleoside-reverse-transcriptase-inhibitors","display_name":"non-nucleoside reverse transcriptase inhibitors","score":0.9480000138282776},{"id":"https://openalex.org/keywords/hiv-1","display_name":"HIV-1","score":0.8080000281333923},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.7749999761581421},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.9570000171661377},{"id":"https://openalex.org/keywords/efavirenz","display_name":"efavirenz","score":0.8420000076293945},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.41100001335144043},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.6840000152587891},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.6349999904632568},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.578000009059906},{"id":"https://openalex.org/keywords/oral-administration","display_name":"oral administration","score":0.38499999046325684},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.47999998927116394},{"id":"https://openalex.org/keywords/antiretroviral-therapy","display_name":"antiretroviral therapy","score":0.5889999866485596},{"id":"https://openalex.org/keywords/electrocardiographic-findings","display_name":"electrocardiographic findings","score":0.4099999964237213},{"id":"https://openalex.org/keywords/vital-signs","display_name":"vital signs","score":0.6520000100135803},{"id":"https://openalex.org/keywords/laboratory-testing","display_name":"laboratory testing","score":0.6610000133514404},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.47200000286102295}],"concepts":[{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.9039132595062256},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9035494327545166},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6892138719558716},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6334056258201599},{"id":"https://openalex.org/C2779225474","wikidata":"https://www.wikidata.org/wiki/Q842424","display_name":"Urinalysis","level":3,"score":0.5334121584892273},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5278033018112183},{"id":"https://openalex.org/C2781432083","wikidata":"https://www.wikidata.org/wiki/Q422645","display_name":"Efavirenz","level":5,"score":0.48876523971557617},{"id":"https://openalex.org/C2777014857","wikidata":"https://www.wikidata.org/wiki/Q1383410","display_name":"Exacerbation","level":2,"score":0.42780429124832153},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4225332736968994},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.20420020818710327},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.1485757827758789},{"id":"https://openalex.org/C77411442","wikidata":"https://www.wikidata.org/wiki/Q181100","display_name":"Urinary system","level":2,"score":0.14257162809371948},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.08367866277694702},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.08228704333305359},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000480","descriptor_name":"Alkynes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003521","descriptor_name":"Cyclopropanes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009570","descriptor_name":"Nitriles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D009570","descriptor_name":"Nitriles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D018894","descriptor_name":"Reverse Transcriptase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D018894","descriptor_name":"Reverse Transcriptase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D048588","descriptor_name":"Benzoxazines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.clinthera.2010.10.007","doi":"https://doi.org/10.1016/j.clinthera.2010.10.007","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.clinthera.2010.10.007","pdf_url":null,"source":{"id":"https://openalex.org/S185879095","display_name":"Clinical Therapeutics","issn_l":"0149-2918","issn":["0149-2918","1879-114X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Therapeutics","raw_type":"journal-article"},{"id":"pmid:21095483","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21095483","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical therapeutics","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":12,"referenced_works":["https://openalex.org/W2003077790","https://openalex.org/W2015082477","https://openalex.org/W2044755757","https://openalex.org/W2121179908","https://openalex.org/W2131582834","https://openalex.org/W2143166782","https://openalex.org/W2148750104","https://openalex.org/W2159944585","https://openalex.org/W2182777591","https://openalex.org/W2183940924","https://openalex.org/W3191280760","https://openalex.org/W4232932066"],"related_works":["https://openalex.org/W2015082477","https://openalex.org/W1940883762","https://openalex.org/W2018845465","https://openalex.org/W4235348208","https://openalex.org/W1975895161","https://openalex.org/W3091783708","https://openalex.org/W2145939627","https://openalex.org/W7100365878","https://openalex.org/W2416139320","https://openalex.org/W2157539481"],"abstract_inverted_index":null,"counts_by_year":[{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}